8-K: Nurix Therapeutics Reports Strong Q3 2026 Results, Advances Key Trials

Nurix Therapeutics announced robust third-quarter 2026 financial results, highlighted by substantial revenue growth, advancement of its bexobrutinib program into Phase 3, and a strong cash position extending runway into late 2029.

Summary

• Nurix Therapeutics reported strong financial results for the fiscal quarter ended August 31, 2026, with revenue reaching $673.1 million, a significant increase from $7.9 million in the prior year period.
• This revenue surge was primarily driven by $653.2 million in license revenue from the Roche collaboration and a $10 million milestone payment from Sanofi.
• The company advanced its bexobrutinib program, dosing the first patient in the Phase 3 DAYBreak CLL-306 trial and initiating recruitment for a Phase 1b/2 combination study.
• NX-1607, an oral CBL-B inhibitor, entered Phase 1b expansion cohorts across multiple solid tumor indications, with the first patient dosed in September 2026.
• Nurix reported $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, 2026, providing runway into the second half of 2029.
• The company also announced the discontinuation of further clinical development for NX-2127 (zelebrudomide) to prioritize its oncology portfolio.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by significant progress in clinical trials, strategic collaborations, and a strong financial position.

Positives

• Significant revenue increase to $673.1 million for Q3 2026, largely due to collaboration revenue from Roche and Sanofi.
• Advancement of bexobrutinib into a Phase 3 registrational trial (DAYBreak CLL-306) for CLL/SLL.
• Initiation of a Phase 1b/2 study for bexobrutinib in combination with standard-of-care therapies.
• NX-1607 entered Phase 1b expansion cohorts for multiple solid tumor indications.
• Strong cash position of $1.1 billion as of August 31, 2026, ensuring financial runway into the second half of 2029.
• Received a $10 million milestone payment from Sanofi for the STAT6 degrader program.
• Extended research term with Gilead for an oncology program, receiving a $10 million fee.
• Bexobrutinib Phase 1a/1b data in CLL showed a median progression-free survival of 22.1 months and an objective response rate of 83.0%.

Negatives

• Discontinuation of further clinical development for NX-2127 (zelebrudomide) to focus resources.
• General and administrative expenses increased significantly to $34.4 million from $13.2 million, attributed to one-time transaction costs for the Roche deal.

Risks

• Uncertainties related to the timing and results of preclinical studies and clinical trials.
• The unexpected emergence of adverse events or other undesirable side effects during clinical development.
• Whether Nurix will be able to fund development activities and achieve development goals, including its obligations under the Nurix-Roche collaboration.
• Uncertainties related to the timing and receipt of payments from collaboration partners, including milestone payments and royalties.
• Whether Nurix and Roche will be able to successfully co-commercialize bexobrutinib in the United States.
• Whether Nurix will be able to protect its intellectual property.

Future Outlook

The company has a strong cash position of $1.1 billion, providing runway into the second half of 2029, and is advancing multiple clinical programs, including bexobrutinib in Phase 3 and NX-1607 in Phase 1b expansion cohorts.

Management Comments

• "The third quarter marked an important transition for Nurix as we moved bexobrutinib into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.
• "At the same time, Sanofi advanced our oral STAT6 degrader into the clinic, and we advanced our CBL-B inhibitor NX-1607 into Phase 1b expansion cohorts across four solid tumor indications."

Industry Context

StockSavvy.ai notes that Nurix's progress aligns with the broader biopharmaceutical industry trend towards targeted protein degradation therapies. The company's strategic collaborations with major players like Roche, Pfizer, and Sanofi underscore the perceived value and potential of its platform in addressing unmet medical needs in oncology and autoimmune diseases.

Comparison to Industry Standards

• The Phase 3 DAYBreak CLL-306 trial for bexobrutinib is a significant step, comparable to other registrational trials for BTK inhibitors in the relapsed/refractory CLL/SLL market.
• The reported objective response rate of 83.0% and median progression-free survival of 22.1 months for bexobrutinib in Phase 1a/1b CLL patients are competitive with existing therapies, though direct comparison requires Phase 3 data.
• The $1.1 billion cash position provides substantial runway, exceeding typical benchmarks for clinical-stage biopharmaceutical companies, enabling continued investment in R&D and clinical development.

Stakeholder Impact

• Shareholders: Positive impact expected from strong financial results, advancement of key drug candidates into later-stage trials, and extended financial runway.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline and collaborations.
• Collaborators (Roche, Pfizer, Sanofi, Gilead): Continued progress in joint development programs and potential for future revenue streams.
• Patients: Potential for new and improved treatment options for cancer and autoimmune diseases through the development of bexobrutinib, NX-1607, and other pipeline candidates.

Next Steps

• Continue enrollment in the Phase 3 DAYBreak CLL-306 study.
• Continue enrollment in the Phase 2 DAYBreak CLL-201 study.
• Continue recruiting for the Phase 1b/2 NX-5948-203 study evaluating bexobrutinib combinations.
• Evaluate NX-1607 in Phase 1b monotherapy expansion cohorts and Phase 1a combination cohort.
• Continue first-in-human Phase 1 study for Gilead's IRAK4 degrader GS-6791.
• Continue Phase 1 first-in-human clinical trial of Sanofi's STAT6 degrader SAR448272/NX-3911.

Key Dates

Recommendation

The filing demonstrates significant clinical and financial progress. The advancement of bexobrutinib into Phase 3, coupled with a strong cash position and strategic collaborations, presents a compelling growth narrative. The positive financial results and robust pipeline advancements suggest a high likelihood of future value creation.

Keywords

Nurix Therapeutics, bexobrutinib, CLL/SLL, Phase 3 trial, targeted protein degradation, biopharmaceutical, oncology, collaboration